Breaking news🔥
US FDA approves EMBLAVEO (aztreonam and avibactam) for complicated intra-abdominal infections (cIAI) in adult patients who have limited or no alternative options #idxposts
Super interesting 🔥
We know Ticagrelor has antibacterial activity against G+ bacteria
Mechanism⁉️
Tica targets multiple lipids in the cytoplasmic membrane of G+ bacteria
➕️
Tica enhances the activity of vanco and dapto without eliciting cross-resistance
https://t.co/9O4szxeMrA
🆕️🔥Narrative Review @CMIJournal
Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians #idxposts#TDM#MRSA
https://t.co/h5IDIMxgD8
K. pneumoniae is capable of resistance to β-lactam antibiotics through expression of β-lactamases and downregulation of outer membrane porins
🆕️🔥Excellent article
What Contributes to the MIC? Beyond β-Lactamase Gene Detection in Klebsiella pneumoniae https://t.co/Q6HuzYBIz7
🚫 Mind blowing 🚫
🆕️🔥Case report @CIDJournal
A fatal case of NDM"5" producing Escherichia coli in a bacteremic patient with sequential failure of Aztreonam+ceftazidime avibactam followed by Cefiderocol #IDXposts#PBP3#AMR https://t.co/BBrMuyEAhQ
Penicillin-Susceptible Streptococcus pneumoniae Meningitis in Adults: Does the Ceftriaxone Dosing Matter? #IDTwitter @ParhamSendi
https://t.co/vOhjbfPe9I
🆕️🌟@ASHE_Journal@TJhaveriMD
A decade of clinical microbiology: top 10 advances in 10 years: what every infection preventionist and antimicrobial steward should know
#IDXposts
https://t.co/kb5LX03xO0